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Abstract
Background: There were few related studies aiming to severe IgA nephropathy (IgAN) which could progress
rapidly to end stage renal disease (ESRD) within ten years. To find valuable clinical or pathological factors and
promising precautions is essential.
Methods: A single center case–control study was performed. Fifty ESRD patients with the primary cause of IgAN
and a short renal survival time of less than ten years after diagnose were enrolled in the case group. One hundred
IgAN patients with a renal survival time of more than ten years were enrolled in the control group. IgA Oxford
classification scores, clinical data at baseline and during the follow-up were collected. Multivariate logistic regression
was used to investigate factors associated with the development of ESRD.
Results: There were significant differences in baseline clinical data between these two groups, as well as the constituent
ratio of Oxford MEST-score. Distinct differences were observed in time-average uric acid(TA-UA), time-average
hemoglobin(TA-Hb), time-average albumin(TA-Alb), time-average total cholesterol(TA-TC) and time-average urinary
protein(TA-P) during the follow-up. In multivariate logistic models, IgA Oxford score M1(OR = 5.10, P = 0.018) and
eGFR(OR = 0.97, P = 0.039) at biopsy, TA-UA (OR = 2.06, P = 0.026) and TA-Hb (OR = 0.53, P = 0.022) during the follow-up
were identified independent factors for developing ESRD.
Conclusion: IgAN patients with pathological assessment of M1, low baseline eGFR, TA-Hb and high TA-UA were more
likely to progress to ESRD, and should be paid more attention. Appropriate regulations of UA, Hb and urine protein after
diagnose may be a promising treatment.
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Background
IgAN is one of the most common glomerulonephritis in
Asian, accounting for 45.26% of primary glomerular dis-
eases in China, and is also a leading cause of ESRD.
Most of the IgAN patients showed good outcomes, but
about 30% of them progressed to ESRD within 10–20
years, while in some patients the disease developed rap-
idly to ESRD within ten years. Clinical and pathological
markers, such as proteinuria, hypertension, decreased
eGFR at the time of biopsy and the MEST score were
found to be associated with renal outcome in previous
studies [1, 2]. It was widely accepted that clinical and
pathological markers above were significant factors for
IgAN development. Compared with numerous studies
on MEST score and clinical data at biopsy, follow-up
features, except for urine protein, were paid little atten-
tion. Even then those follow-up data were still of great
importance [3, 4]. The main purpose of this study was
to assess the prognostic value of these follow-up clinical
data, including TA-P, TA-UA, TA-Alb, TA-Hb and TA-
TC, on the progression of progressive IgAN and also to
reassess the predictive value of MEST score and clinical
features at biopsy. This could be practical to the full
stage guidance of IgAN treatment.* Correspondence: cnsuzhen@hotmail.com
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Methods
Study design and participants
This was an observational case–control study. Fifty end
stage renal disease patients with the primary cause of
IgAN and a short renal survival time of less than ten
years after renal biopsy were enrolled in case group. One
hundred IgAN patients with a renal survival time of
more than ten years after biopsy were reviewed as con-
trol group. Patients enrolled in this study were given the
diagnosis of primary IgAN between 1997 and 2012 in
the First Affiliated Hospital of Wenzhou Medical Uni-
versity. Exclusion criteria for both groups included: renal
biopsy conducted in other hospitals, a secondary cause
of IgAN, such as Henoch-Schonlein purpura, systemic
lupus erythematosus, chronic liver disease and other
autoimmune disorders, aged <18 years at biopsy and his-
tory of cardiovascular events, carotid artery surgery or
any organ transplantation.
Clinical and pathological data
Baseline clinical data, including gender, age, sCr, Hb,
Alb, UA, TC, 24 h urine protein, hypertension and self-
reported hematuria history, were obtained from the ori-
ginal medical records of each patient. Follow-up clinical
data, including sCr, UA, Alb, Hb, TC and urine protein
levels as well as the observation date at each checkup
before the point of ESRD in cases or the last follow-up
in controls were recorded. Renal survival time was
accounted from biopsy to the point of ESRD or the last
follow-up. For each patient, the average level (time-
weighted average) of each clinic feature (UA, Alb, Hb,
TC and urinary protein) were calculated from the area
under the curve of serial measurements standardized by
the length of the study. The kidney specimen of every
patient was reviewed according to the Oxford classifica-
tion [5]. eGFR was calculated by modified MDRD equa-
tion: eGFR[ml · min−1 · (1.73 m2)−1] = 175 × [Scr, mg/dl]-
1.234 × [age]-0.179[×0.79(if female)]. ESRD was defined as
eGFR < 15 ml · min−1 · (1.73 m2)−1 or initiation of dialysis
or transplantation. During the follow-up, most of the
urinary protein tests were semi-quantified with a stand-
ard urine dipstick with (−), (±), (+), (++), (+++) and (++
++) corresponding to <0.1, 0.1-0.2, 0.2-1.0, 1.0-2.0, 2.0-
4.0 and >4.0 g/L of urine albumin, respectively. In this
study we quantified (−) (±) to 0, (+) to 0.6, (++) to 1.5,
(+++) to 3, (++++) to 4 g/L [6], respectively.
Statistical analysis
Statistical analysis was performed using SPSS17.0 soft-
ware. Qualitative variables were expressed as number
and percentage, compared using the unpaired t-test
(Student’s t-test), the Mann–Whitney U test or Spear-
man correlation. Continuous variables were expressed as
mean values ± standard deviation when normally
distributed, or median(range) when not, and data were
compared using the chi-square test or Fisher’s exact test
or the Mann–Whitney U test, one-way ANOVA or Pear-
son correlation. Univariate logistic regression and multi-
variate logistic regression were used to determine factors
to outcomes. A significance level of 0.05 was accepted.
Result
Baseline clinical data
A total of one hundred and fifty patients with a primary
cause of IgAN were enrolled in this study. The median
renal survival time in case group (fifty cases) was
67 months (1–120 months) with the initial CKD stage at
the time of renal biopsy: CKD I 8 cases (16.0%), CKD II
12 cases (24.0%), CKD III 23 cases (46.0%), CKD IV 7
cases (14.0%). In control group (one hundred cases), the
median renal survival time was 132 months (112–200
months), with the initial CKD stage at biopsy: CKD I 55
cases (55%), CKD II 35 cases (35%), CKD III 9 cases
(9%), CKD IV 1 case (1%).
The case group had significantly higher frequencies of
M1, S1, T1 and T2 score (P < 0.05) and higher levels of
sCr, UA, TC, 24 h urinary protein and the proportion of
hypertension at biopsy than in control group (P <0.05),
while Hb, Alb, eGFR and the proportion of hematuria
history were lower than those in control group (P <0.05)
(Table 1).
Clinical features during the follow-up
Average levels of each clinical feature during the follow-
up were calculated and compared. Figure 1a shows an
example of serial measurements of UA during the
follow-up of one patient and the equation to calculate
the TA-UA in current study [7]. Similarly, TA-P, TA-Hb,
TA-Alb and TA-TC of each patient were calculated by
the same method. As shown in Fig. 1, there were re-
markable differences in TA-P [2.5 (0.5–4.2) versus 0.6
(0–2.4) g/L; P <0.001], TA-UA [7.8 ± 1.7 versus 5.8 ±
1.4 mg/dl; P <0.001], TA-Hb [11.7 ± 2.0 versus 13.3 ±
2.0 g/dl; P <0.001], TA-Alb [3.8 (2.0–4.7) versus 4.3
(3.0–5.8) g/dl; P <0.001] and TA-TC [212.3 (116.0–
394.4) versus 194.7 (112.1–296.2) mg/dl; P = 0.011] be-
tween cases and controls.
Risk assessment by univariate and multivariate logistic
analysis
Clinical and pathological data were analyzed by logistic
regression to identify whether were they associated with
developing of ESRD among those patients (Table 2),
whereas TA-P was excluded here because of its inaccur-
ate property. TA-P in this study was estimated from
semi-quantified urine protein measurement, which may
not be able to reflect the accurate level of urine protein
compared with albumin creatinine ratio or 24 h urine
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protein measurement, and may cause statistical bias in
multivariate analysis. Univariate logistic analysis indi-
cated that Oxford classification: M1, S1, T1 or T2, high
UA, TC, 24 h urine protein levels, the hypertension his-
tory at biopsy and high TA-UA, TA-TC during the
follow-up were associated with an increased risk for de-
veloping ESRD, while high levels of baseline eGFR, Hb
and Alb, TA-Hb and TA-Alb during the follow-up and
the present of macro-hematuria were associated with a
decreased risk of ESRD. The risk to develop ESRD of all
these clinical and pathological features were further
assessed in multivariate logistic regression analysis. The
result showed: M1(OR = 5.10, P = 0.018), eGFR at biopsy
(OR = 0.97, P = 0.039), TA-UA (OR = 2.06, P = 0.026) and
TA-Hb (OR = 0.53, P = 0.029) were independent factors
for developing ESRD among IgAN patients.
Discussion
IgAN is the leading cause of adult primary glomerulo-
nephritis progressing to ESRD [8]. However, there is still
a lack of specific therapeutic interventions, because of
the unclearness of its etiology and pathogenesis, so early
identification of risk factors and timely treatment may
be essential to the renal outcome. Progressive IgAN,
which progress to ESRD within ten years, only
accounted for a small part of IgAN population and nor-
mally were studied along with patients under stable con-
dition, for instance, remaining normal renal function
and slowly developing sCr, by retrospective cohort study
[6, 9], which means some characteristics of progressive
IgAN may be covered by the stable one. In this study, as
the main object, progressive IgAN patients were com-
pared with patients under stable renal conditions to
identify the risk factors of poor prognosis, aiming to
provide a promising guidance for the further treatment.
Impaired renal function, consistent proteinuria with
more than 1 g per day and Oxford pathological score
T1/T2 were recognized as independent risk factors for
IgAN in a couple of previous studies [5, 7]. However, a
great number of those founding was based on clinical
and pathological data at the time of biopsy, with the ab-
sence of follow-up data. In this study, those factors were
further considered with the present of follow-up fea-
tures. In statistical practice (Additional file 1), variables
were put into the logistic regression mode one by one to
dig underlying information between them. When only
MEST scores were included in the multivariate logistic
analysis (Additional file 1, mode 1), M1, T1 and T2 were
adverse prognostic factors to ESRD, but the OR value of
them decreased and even showed no significance with
the entrance of eGFR at biopsy (Additional file 1, mode
2). This could be explained by the strong correlation be-
tween MEST score and eGFR (Additional file 2), indicat-
ing eGFR may be a better predictor for renal outcome
than T2 in severe IgAN. This situation maintained until
the participant of demographic and baseline laboratorial
data, including gender, age, UA, Hb, Alb, TC and 24 h
urinary protein (Additional file 1, mode 8), in which
score T and eGFR lost its position and gender (male) ap-
peared to be a strong risk factor to unfavorable progno-
sis. The complex cross-relation among score T, gender,
baseline eGFR, UA, Hb and Alb may contribute to this
result (Additional file 2). In addition, there are innate
difference between males and females in the normal
range of UA and Hb. The situation changed again when
follow-up clinical data were enrolled (Additional file 1,
Table 1 Baseline clinical data








At time of biopsy Mesangial hypercellularity **
Gender (M/F) 35/15 56/44 M0 11 (22.0%) 72 (72.0%)
Age (y) 35.8 ± 9.9 35.4 ± 10.1 M1 39 (78.0%) 28 (28.0%)
eGFR 57.3 ± 27.6** 95.7 ± 32.7 Endocapillary hypercellularity
sCr (mg/dl) 1.4 (0.8–4.3)** 0.9 (0.5–2.1) E0 14 (28.0%) 32 (32.0%)
UA (mg/dl) 8.0 (1.9–15.3)** 5.7 (2.3–12.9) E1 36 (72.0%) 68 (68.0%)
Hb (g/dl) 12.2 ± 2.0* 12.9 ± 1.8 Segmental Glomerulosclerosis*
Alb (g/dl) 3.5 ± 0.8* 3.9 ± 0.6 S0 12 (24.0%) 52 (52.0%)
TC (mg/dl) 207.7 (111.5–392.3)* 184.6 (100.0–369.2) S1 38 (76.0%) 48 (48.0%)
Proteinuria (g/day) 2.9 (0.1–8.3)** 0.8 (0–9.9) Tubular atrophy/Interstitial fibrosis**
Hypertension 31 (62.0%)* 47 (47.0%) T0 16 (32.0%) 86 (86.0%)
Macro-hematuria 2 (4.0%)* 18 (18.0%) T1 26 (52.0%) 11 (11.0%)
T2 8 (16.0%) 3 (3.0%)
eGFR estimated glomerular filtration rate (ml · min-1 · (1.73 m2)-1), sCr serum creatinine, UA uric acid, Hb hemoglobin, Alb serum albumin, TC total cholesterol
*P < 0.05; **P < 0.001
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mode 11). Then eGFR came back to the predictor group
instead of gender. This mode showed the relevance of
follow-up clinical features more than those at biopsy.
TA-P, though not that credible, showed a significant im-
pact on renal outcome in mode 15 (Additional file 1). In
general, stepwise logistic analysis illustrated that correla-
tions between clinical data were inevitable and results of
statistical analysis can be various with different variates
in the analysis mode, and multivariate analysis was a
proper way to distinct the strongest factors.
In previous studies, Oxford pathological score T was
highly recognized as an important predictor of develop-
ing ESRD [9, 10], while roles M, E and S played were
controversy. The Oxford score of 1026 primary IgAN
patients from 18 clinical research centers in China were
compared with the data in the original IgAN Oxford
classification study [11]. Then a higher ratio of M1 and
E1 and a lower ratio of S1 were observed in Chinese
population, while the proportion of T1/T2 between
them was similar. In this study, M1, T1 and T2 were
identified as risk factors when only Oxford score were
included in the logistic regression (Additional file 1,
mode 1), but only M1 remained as an independent fac-
tor in multivariate analysis. Although T did not maintain
a marked role in multivariate analysis, it was also of
great importance because of its correlation with most
variates in this study (Additional file 2). Combined with
the results, we came up with a hypothesis that patho-
logical score M1 might be a risk factor for progressing
to ESRD in Chinese IgAN population.
There was an increasing attention on the relationship
between hyperuricemia [12] and chronic kidney disease
[13]. High concentration of serum UA may lead to ne-
phropathy and renal function impairment by directly
mechanical damage or indirectly inflammation and cell
phenotype inversion, resulting in the reduction of UA
Fig. 1 Clinical features during follow-up. a, Serial measurements of proteinuria during follow-up in one patient and the definition of TA-P for this
patient. Comparison of TA-P (b), TA-UA (c), TA-Hb (d), TA-Alb (e) and TA-TC (f). Dotted lines present the normal range of each clinical feature.
Median and interquartile range were presented in each figure
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excretion and forming a vicious cycle. Normal ranges of
Hb and Alb were also reported beneficial to stable in-
ternal environment and normal physiological activities
[14, 15]. Theories above could provide our result with
support that serum UA and Hb levels during the follow-
up can significantly affect the progress of IgAN to ESRD.
Although TA-P was excluded from the final multivariate
analysis for the accuracy of the mode, the importance of
it cannot simply be ignored (Additional file 1, mode 15)
and it had also long been recognized as a strong and re-
liable factor to renal outcome [16, 17].
Our research did not only come up with a similar re-
sult with others that M1, T1/T2 and eGFR at biopsy
were strongly related to IgAN outcome, but also first as-
sess the role TA-UA, TA-Hb, TA-Alb and TA-TC played
in IgAN progressing and come up with a clinically sig-
nificant result that TA-UA and TA-Hb were independ-
ent factors for developing ESRD. One of the limitation
of this study was its retrospective nature, which means
the data we collected was restricted. There was also a se-
lection bias: patients enrolled were those who followed
up in our hospital for a long term, so they might not be
a fully presentative sample of the general population. A
long-term prospective study or a clinical trial may be
better for the study of IgAN treatment.
Conclusions
In summary, patients with pathological assessment of
M1, T1 or T2, an impaired renal function, abnormal
blood biochemical parameters and hypertension at
Table 2 Predictive factors for ESRD by univariate and multivariate logistic regression
Univariate Logistic Multivariate Logistic
OR (95%CI) P OR (95%CI) P
Mesangial hypercellularity
M0 1 1
M1 9.12 (4.10–20.27) <0.001 5.10 (1.33–19.60) 0.018
Endocapillary hypercellularity
E0 1 1
E1 1.21 (0.57–2.55) 0.617 1.62 (0.33–8.02) 0.557
Segmental Glomerulosclerosis
S0 1 1
S1 3.43 (1.61–7.32) 0.001 0.57 (0.12–2.74) 0.480
Tubular atrophy/interstitial fibrosis
T0 1 1
T1 12.71 (5.25–30.76) <0.001 1.82 (0.33–10.0) 0.492
T2 14.33 (3.43–59.91) <0.001 0.32 (0.02–5.48) 0.431
At the time of biopsy
eGFR 0.96 (0.94–0.97) <0.001 0.97 (0.93–0.998) 0.039
Gender (male) 1.83 (0.89–3.78) 0.100 5.38 (0.82–35.49) 0.081
Age 1.0 (0.97–1.04) 0.830 0.92 (0.83–1.01) 0.087
UA 1.74 (1.39–2.16) <0.001 0.94 (0.59–1.50) 0.795
Hb 0.82 (0.68–0.99) 0.039 1.14 (0.60–2.17) 0.692
Alb 0.40 (0.24–0.67) 0.001 0.53 (0.18–1.62) 0.267
TC 1.01 (1.0–1.02) 0.006 1.003 (0.99–1.02) 0.687
24 h urine protein 1.60 (1.30–1.96) <0.001 1.17 (0.86–1.58) 0.313
Hypertension (yes) 1.84 (0.92–3.68) 0.085 4.33 (0.79–23.80) 0.092
Macro-hematuria (yes) 0.19 (0.04–0.85) 0.030 0.05 (0–9.02) 0.264
Follow-up
TA-UA 2.36 (1.74–3.19) <0.001 2.06 (1.09–3.90) 0.026
TA-Hb 0.61 (0.48–0.76) <0.001 0.53 (0.30–0.91) 0.029
TA-Alb 0.18 (0.08–0.38) <0.001 0.48 (0.10–2.37) 0.367
TA-TC 1.01 (1.0–1.02) 0.002 1.004 (0.99–1.02) 0.697
OR odds ratio, 95% CI 95% confidence interval
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biopsy should be paid more attention, and therapies
aiming to keep UA and Hb levels under the control and
reduce urinary protein during the follow-up are highly
recommended. Pathological type M may play an import-
ant role in IgAN outcomes among Chinese population.
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detailed results in every step of stepwise multivariate logistic analysis.
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